Critical Therapeutics (CRTX) is having a hell of a run today. The stock is up 31% to $3.50 on almost 11.8 million shares. At one point, the share hit $4.10.
The reason? The Food and Drug Administration approved its chronic asthma drug. Cowen & Co."predicted the franchise will bring the company $125 million in revenue in 2011." The product is marketed with Merck KGaA.
The stock increase brings the CRTX market cap to $150 million.
In the last quarter, the company had revenue of $3.5 million and an operating loss of $5.2 million. The company has about $45 million in cash.
Is the stock worth the much higher price. Perhaps. But, the company is small and investors might like to see it bought at this price. Takes away what appear to be a huge risk.
Douglas A. McIntyre
Sponsored: Find a Qualified Financial Advisor
Finding a qualified financial advisor doesn’t have to be hard. SmartAsset’s free tool matches you with up to 3 fiduciary financial advisors in your area in 5 minutes. Each advisor has been vetted by SmartAsset and is held to a fiduciary standard to act in your best interests. If you’re ready to be matched with local advisors that can help you achieve your financial goals, get started now.
Thank you for reading! Have some feedback for us?
Contact the 24/7 Wall St. editorial team.
Editors' Picks
